November 04, 2024
Developing treatments for people with mental health conditions
October 14, 2024
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare
October 09, 2024
Boehringer Ingelheim collaborates with Circle Pharma
October 08, 2024
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
September 27, 2024
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
September 25, 2024
Boehringer Ingelheim expands cancer research at its Vienna site
September 16, 2024
Nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
September 09, 2024
Zongertinib shows encouraging efficacy and tolerability profile in lung cancer patients
September 05, 2024
Geographic Atrophy treatment to move to Phase II
September 03, 2024
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
August 30, 2024
Boehringer Ingelheim announces appointments Board of Managing Directors
August 27, 2024
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC
July 29, 2024
Boehringer Ingelheim acquires Nerio Therapeutics
July 29, 2024
CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®
July 18, 2024
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
July 08, 2024
Boehringer Ingelheim produces its own green energy
July 03, 2024
Boehringer Ingelheim advances SIRPα immuno-oncology program
July 01, 2024
Phase 1 start for novel triple agonist obesity treatment
June 07, 2024
Survodutide shows breakthrough improvement in liver fibrosis
May 28, 2024
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
May 22, 2024
Partnership for first-in-class cancer and CRM treatments
May 13, 2024
BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3)
May 06, 2024
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia
April 25, 2024
World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated
April 16, 2024
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
April 09, 2024
Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
April 06, 2024
Results announced from EMPACT-MI phase III trial
March 19, 2024
SPEVIGO® approved for expanded indications in China and the US
March 11, 2024
New partnership to develop schizophrenia treatments
February 26, 2024
Survodutide Phase II trial shows groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
February 19, 2024
The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone.
February 08, 2024
Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
January 18, 2024
Global Top Employer 2024 certification reflects Boehringer Ingelheim’s impactful people development
January 11, 2024
Boehringer expands production site in Greece for new medicine
January 10, 2024
SENVELGO® wins Best New Product for Companion Animals award
January 09, 2024
Kicking off 2024 with five new R&D partnerships
January 09, 2024
New study paves the way for liver cirrhosis treatments
January 05, 2024
Boehringer Ingelheim licenses a new compound as part of its commitment to people living with fibro-inflammatory diseases from Kyowa Kirin
January 04, 2024
Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies
January 03, 2024
Partnership for new liver disease treatments with Ribo
December 18, 2023
Boehringer Ingelheim announces appointments Board of Managing Directors
November 28, 2023
Partnership with IBM to accelerate new antibody therapies
November 23, 2023
Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats
November 22, 2023
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
November 03, 2023
Boehringer Ingelheim achieves major milestone in chronic kidney disease
October 30, 2023
Life forward - Boehringer Ingelheim unveils its evolved company brand
October 30, 2023
SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
October 05, 2023
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
October 02, 2023
Phase 1 start of treatment for Geographic Atrophy patients
October 02, 2023
Partnership with Precision Health Research, Singapore
October 02, 2023
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
September 14, 2023
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets
September 05, 2023
New partnership working on solutions to combat African animal trypanosomiasis
August 17, 2023
Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity
August 14, 2023
Boehringer Ingelheim receives FDA approval for SENVELGO®: the first oral liquid medication for diabetes in cats
August 01, 2023
First half of 2023: strong growth and expansion in key therapy areas
July 28, 2023
FRONTLINE® wins Brand of the Year Award for the third time in a row
July 25, 2023
Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
July 20, 2023
Boehringer Ingelheim receives FDA approval for NexGard® PLUS: a beef-flavored soft chew that protects dogs from internal and external parasites
July 04, 2023
Spesolimab prevents GPP flares
June 23, 2023
Phase II trial data shows nearly 19% weight loss in people with overweight or obesity
June 23, 2023
Jardiance® recommended for the treatment of adults with chronic kidney disease in the EU
May 10, 2023
Phase II trial results in people living with obesity or overweight
May 09, 2023
IL-11 inhibitor antibody clinical development launched
May 02, 2023
Breakthrough Designation granted in US and China
May 02, 2023
Boehringer and German Chancellor Olaf Scholz lay the foundation stone for EUR 285 million innovation center
April 24, 2023
Boehringer inaugurates largest European development centre for biotechnology
March 29, 2023
Boehringer Ingelheim reaches more patients than ever, innovation drives growth
March 02, 2023
LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine
January 30, 2023
Spesolimab meets key endpoint for GPP flare prevention
January 24, 2023
FDA accepts application for new CKD treatment
January 17, 2023
Global Top Employer 2023
January 09, 2023
New cancer therapeutics collaboration with 3T Bio
December 20, 2022
Boehringer Ingelheim announces appointments to Board of Managing Directors
December 19, 2022
New digital Tx collab with Click
December 13, 2022
EC grants conditional marketing authorization for spesolimab
December 07, 2022
Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes
November 04, 2022
Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease
October 26, 2022
FIBRONEER™ Phase III program initiated in over 40 countries
October 20, 2022
AI and Data Science Fellowship with University of Tuebingen
October 14, 2022
CHMP recommends conditional approval for first GPP treatment
October 10, 2022
Bridging science and veterinary practice for swine health: The winners of the European PRRS Award 2022
October 05, 2022
Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements
September 06, 2022
Boehringer Ingelheim launches Fencovis®, a new vaccine to prevent calf diarrhea
September 05, 2022
New data for nintedanib in children with fibrosing interstitial lung disease
September 02, 2022
First approval for SPEVIGO® to treat GPP flares
August 03, 2022
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
July 06, 2022
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
June 14, 2022
Option to Acquire Trutino Biosciences
June 14, 2022
Boehringer Ingelheim and CarthroniX announce partnership to pursue small molecule therapeutics in canine oncology
June 06, 2022
Jardiance® (empagliflozin) decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study
June 02, 2022
A*STAR antibodies bolster ADC and T-Cell engager development
May 15, 2022
Investigational treatment slowed lung function decline in IPF
May 12, 2022
TwistPak®: Mixing platform for swine vaccines brings convenience and flexibility
May 11, 2022
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
April 21, 2022
Boehringer Ingelheim launches RenuTend™: a new stem cell therapy to improve the healing of tendon and suspensory ligament injuries in horses
April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in Research and Development
March 29, 2022
Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
March 28, 2022
New spesolimab data show significant improvement in GPP flares
March 22, 2022
Boehringer Ingelheim and the World Association for Buiatrics support outstanding research on ruminant animal health and well-being
March 16, 2022
Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
March 07, 2022
Jardiance® (empagliflozin) becomes the first and only approved treatment in Europe for adults with symptomatic chronic heart failure regardless of ejection fraction
March 01, 2022
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
March 01, 2022
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
February 25, 2022
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
February 24, 2022
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
February 09, 2022
New criteria for the susceptibility testing of Ubrolexin® when treating mastitis in dairy cows
January 28, 2022
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
Media Contacts
Head of Global Media Relations
E-Mail:
harro.ten_wolde@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-181352
Senior Media Relations Manager
E-Mail:
tereza.urbankova@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-184817
Head of Human Pharma Communications
E-Mail:
anthonia.aboyeji@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-172370
Head of Animal Health Communications
E-Mail:
Heidi.DeWit-Sommerfeld@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-171799